RASSF1 and breast cancer: Furthermore, RASSF1A promoter hypermethylation was reported as a prognostic indicator in renal cell carcinoma, non-small cell lung cancer, neuroblastoma, melanoma, endometrial cancer and breast cancer [11]–[18].